Car enzymes and improved production of fatty alcohols

US11034937B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11034937-B2
Application numberUS-201916414550-A
CountryUS
Kind codeB2
Filing dateMay 16, 2019
Priority dateApr 2, 2012
Publication dateJun 15, 2021
Grant dateJun 15, 2021

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The disclosure relates to variant carboxylic acid reductase (CAR) enzymes for the improved production of fatty alcohols in recombinant host cells.

First claim

Opening claim text (preview).

What is claimed is: 1. A variant carboxylic acid reductase (CAR) polypeptide comprising an amino acid sequence having at least 85% sequence identity to the wild-type CAR polypeptide of SEQ ID NO: 7, wherein the variant CAR polypeptide is genetically engineered to have at least one mutation at an amino acid position selected from the group consisting of E636K; L1128S; M259I; T396S; A574T; T90M; E20F; E20L; E20Y; V191A; Q473A; Q473F; Q473K; Q473M; Q473R; Q473V; V926G; S927I; S927V; L1128A; L1128G; L1128K; L1128M; L1128P; L1128R; L1128T; L1128V; L1128Y; D18V and D292N; E20K and V191A; P809L and M1062V; D143E and A612T; M1062T and R1080H; E936K, and P1134R; I870V, S927I, S985I, and I1164F; L799M, V810F, S927R, M1062L, A1158V, and F1170I; and L80Q, T231M, F288L, A418T, V530M, A541V, G677D, and P712A, wherein expression of the variant CAR polypeptide in a recombinant host cell results in a higher titer of fatty alcohol compositions compared to a recombinant host cell expressing the wild type CAR polypeptide of SEQ ID NO:7. 2. The variant CAR polypeptide of claim 1 , wherein said variant polypeptide comprises: (a) the mutations P809L and M1062V; (b) the mutations D143E and A612T; (c) the mutations M1062T and R1080H; (d) the mutations E936K, and P1134R; (e) the mutations I870V, S927I, S985I, and I1164F; (f) the mutations L799M, V810F, S927R, M1062L, A1158V, and F1170I; or (g) the mutations L80Q, T231M, F288L, A418T, V530M, A541V, G677D, and P712A. 3. A recombinant host cell comprising a polynucleotide sequence encoding a variant carboxylic acid reductase (CAR) polypeptide having at least 85% sequence identity to the wild-type CAR polypeptide of SEQ ID NO: 7 and having at least one mutation at an amino acid position selected from the group consisting of E636K; L1128S; M259I; T396S; A574T; T90M; E20F; E20L; E20Y; V191A; Q473A; Q473F; Q473K; Q473M; Q473R; Q473V; V926G; S927I; S927V; L1128A; L1128G; L1128K; L1128M; L1128P; L1128R; L1128T; L1128V; L1128Y; D18V and D292N; E20K and V191A; P809L and M1062V; D143E and A612T; M1062T and R1080H; E936K, and P1134R; I870V, S927I, S985I, and I1164F; L799M, V810F, S927R, M1062L, A1158V, and F1170I; and L80Q, T231M, F288L, A418T, V530M, A541V, G677D, and P712A, wherein the recombinant host cell produces a fatty alcohol composition at a higher titer or yield than a host cell expressing the wild type CAR polypeptide of SEQ ID NO: 7 when cultured in a medium containing a carbon source under conditions effective to express said variant CAR polypeptide. 4. The recombinant host cell of claim 3 , further comprising a polynucleotide encoding a thioesterase polypeptide. 5. The recombinant host cell of claim 4 , further comprising a polynucleotide encoding (i) a FabB polypeptide and a FadR polypeptide, or (ii) a fatty aldehyde reductase. 6. The recombinant host cell according to claim 3 , wherein said recombinant host cell has a titer or a yield that is at least 3 times greater than the titer or the yield of a host cell expressing the corresponding wild type CAR polypeptide when cultured under the same conditions as the recombinant host cell. 7. The recombinant host cell of claim 6 , wherein said recombinant host cell has a titer of from 30 g/L to 250 g/L, or a titer of from 90 g/L to 120 g/L. 8. The recombinant host cell of claim 6 , wherein said recombinant host cell has a yield from 10% to 40%. 9. A cell culture comprising the recombinant host cell of claim 3 . 10. The cell culture of claim 9 , wherein said cell culture has productivity that is at least 3 times greater than the productivity of a cell culture that expresses the corresponding wild type CAR polypeptide. 11. The cell culture of claim 10 , wherein said productivity ranges from 0.7 mg/L/hr to 3 g/L/hr. 12. The cell culture of claim 11 , wherein the culture medium comprises a fatty alcohol composition. 13. The recombinant host cell according to claim 3 , wherein the fatty alcohol composition collects in an organic phase extracellularly. 14. The recombinant host cell of claim 13 , wherein the fatty alcohol composition comprises one or more of a C6, C8, C10, C12, C13, C14, C15, C16, C17, or C18 fatty alcohol. 15. The recombinant host cell of claim 13 , wherein the fatty alcohol composition comprises a C10:1, C12:1, C14:1, C16:1, or a C18:1 unsaturated fatty alcohol. 16. The recombinant host cell of claim 13 , wherein the fatty alcohol composition comprises C12 and C14 fatty alcohols. 17. The recombinant host cell of claim 16 , wherein the fatty alcohol composition comprises C12 and C14 fatty alcohols at a ratio of 3:1. 18. The recombinant host cell of claim 13 , wherein the fatty alcohol composition comprises unsaturated fatty alcohols or saturated fatty alcohols. 19. The recombinant host cell of claim 18 , wherein the fatty alcohol composition comprises an unsaturated fatty alcohol having a double bond at position 7 in the carbon chain between C7 and C8 from the reduced end of the fatty alcohol. 20. The recombinant host cell of claim 13 , wherein the fatty alcohol composition comprises branched chain fatty alcohols. 21. A method of making a fatty alcohol composition at a high titer, yield or productivity, comprising the steps of: (a) engineering a recombinant host cell according to claim 3 ; (b) culturing said recombinant host cell in a medium comprising a carbon source; and (c) isolating said fatty alcohol composition from said medium.

Assignees

Inventors

Classifications

  • Biofuels, e.g. bio-diesel · CPC title

  • Thioester hydrolases (3.1.2) · CPC title

  • Beta-ketoacyl-acyl-carrier-protein synthase I (2.3.1.41) · CPC title

  • Long-chain-fatty-acyl-CoA reductase (1.2.1.50) · CPC title

  • acting on ester bonds (3.1) · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11034937B2 cover?
The disclosure relates to variant carboxylic acid reductase (CAR) enzymes for the improved production of fatty alcohols in recombinant host cells.
Who is the assignee on this patent?
Genomatica Inc
What technology area does this patent fall under?
Primary CPC classification C12N9/0008. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Jun 15 2021 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 3 related publications on this page (citations in our corpus or others sharing the same primary CPC).